Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329106 | 0.80 | PTGS2 (0.37) | AGTR1POLBSMN1; SMN2ABCG2 | |
| SCHEMBL9429714 | 0.80 | ABCG2 (0.36) | AGTR1POLBSMN1; SMN2ABCG2 | |
| SCHEMBL3326379 | 0.79 | AGTR1 (0.35) | AGTR1POLBSMN1; SMN2 | |
| SCHEMBL3328019 | 0.77 | MAPK14 (0.43) | POLBSMN1; SMN2 | |
| SCHEMBL3327277 | 0.76 | ALDH1A1 (0.33) | AGTR1SMN1; SMN2ABCG2 | |
| SCHEMBL22846841 | 0.75 | CYP3A4 (0.35) | AGTR1POLBSMN1; SMN2 | |
| SCHEMBL9034442 | 0.75 | NPC1 (0.36) | AGTR1POLBSMN1; SMN2 | |
| SCHEMBL30743612 | 0.75 | ABCG2 (0.55) | AGTR1POLBSMN1; SMN2ABCG2 | |
| SCHEMBL4638378 | 0.74 | SMN1; SMN2 (0.51) | POLBSMN1; SMN2 | |
| SCHEMBL3328509 | 0.74 | AGTR1 (0.39) | AGTR1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | DENOVAMED INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| WO-2008128321-A1 | THERAPEUTIC PRO-ANTIBIOTIC AGENTS AND METHODS OF USE THEREOF | DENOVAMED INC. (CA) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | NAT1, NAPEPLD, NR1I2 | AGTR1 2359/4885POLB 2264/4885SMN1; SMN2 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.